Skip to main content
Fig. 3 | BMC Pulmonary Medicine

Fig. 3

From: Protective effect of bevacizumab on chemotherapy-related acute exacerbation of interstitial lung disease in patients with advanced non-squamous non-small cell lung cancer

Fig. 3

Kaplan–Meier comparisons in the Bev and non-Bev groups. a Progression-free survival (PFS). b Overall survival (OS). Crosses denote censoring events. There was a significant difference in median PFS between the Bev (dotted line) and non-Bev (solid line) groups (p = 0.026). NR., not reached

Back to article page

BMC Pulmonary Medicine

ISSN: 1471-2466

Contact us